The impact of the new WHO classification of renal cell carcinoma on the diagnosis of hereditary leiomyomatosis and renal cell carcinoma
Por:
Degenhardt, J, Tolkach, Y, Amin, MB, Mosiello, G, Baydar, DE, Gall, ECL, Dicola, J, Elhag, D, Frezza, C, Halbritter, J, Blanco, I, Jewett, MAS, Lattouf, JB, Lovitt, G, Lundgren, PO, Maher, ER, Mulders, P, Shuch, B, Hartmann, A and Mueller, RU
Publicada:
1 jul 2025
Ahead of Print:
1 abr 2025
Resumen:
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is caused by heterozygous germline variants in the fumarate hydratase (FH) gene. Inheritance follows an autosomal dominant pattern. Loss of FH confers a predisposition for various benign and malignant neoplasms, including cutaneous leiomyomas, uterine fibroids and FH-deficient renal cell carcinoma. While benign, cutaneous and uterine manifestations have a relevant impact on quality of life and risk for complications, the vast majority of FH-deficient RCCs exhibit an aggressive behaviour with invasive growth and the potential for early metastatic spread. Additionally, pathogenic germline FH variants have been associated with other neoplasms, such as adrenal gland and Leydig cell tumours. The aggressive behaviour of FH-deficient RCC challenges nephron-sparing resection strategies, as a wide margin is recommended. Even after early nephrectomy for surgical removal of FH-deficient renal cell carcinomas, there is a relevant risk for distant metastasis as well as the remainingpredisposition for de novo primary renal tumours in the other kidney. Active screening is central to HLRCC care since no preventative HLRCC-specific treatment exists. Vascular endothelial growth factor/epidermal growth factor receptor-directed treatment regimes, such as erlotinib/bevacizumab, demonstrate efficacy against HLRCC-associated RCC. This emphasizes the importance of establishing the correct diagnosis in HLRCC early on to guide therapeutic decisions. Morphologic criteria as well as specific immunohistochemical staining and molecular genetics allow the identification of FH-deficient RCC. Changes made in the recent 2022 World Health Organization classification impact the diagnosis of HLRCC in multiple ways. This commentary aims to discuss this impact and raise awareness among pathologists as well as clinicians involved in the care of patients with HLRCC.
10.1093/ndt/gfaf032 Video Abstract Watch the video abstract of this contribution at https://academic.oup.com/ndt/pages/author_videos gfaf032Media1 6371303830112
Filiaciones:
Degenhardt, J:
Univ Cologne, Dept Internal Med 2, Cologne, Germany
Tolkach, Y:
Univ Hosp Cologne, Inst Pathol, Cologne, Germany
Amin, MB:
Univ Tennessee, Coll Med, Dept Pathol & Lab Med, Hlth Sci Ctr, Memphis, TN USA
Univ Southern Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA
Mosiello, G:
Bambino Gesu Childrens Hosp IRCCS, Div Pediat Urol Neurourol, Rome, Italy
Baydar, DE:
Koc Univ, Sch Med, Dept Pathol, Istanbul, Turkiye
Gall, ECL:
Univ Brest, Ctr Reference Malad Renales Hereditaires l'Enfant, UMR 1078, GGB ,CHU Brest, Brest, France
Dicola, J:
HLRCC Fdn, Coralville, IA USA
Elhag, D:
HLRCC Fdn, Coralville, IA USA
John Stoddard Canc Ctr, Coralville, IA USA
Frezza, C:
Univ Cologne, Fac Med, Cologne, Germany
Univ Hosp Cologne, Inst Metabol Ageing, Cluster Excellence Cellular Stress Responses Aging, Cologne, Germany
Univ Cologne, Inst Genet, Cluster Excellence Cellular Stress Responses Aging, Fac Math & Nat Sci, Cologne, Germany
Halbritter, J:
Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany
:
Hosp Germans Trias i Pujol, Dept Clin Genet, Badalona, Spain
Jewett, MAS:
Int Kidney Canc Coalit, Utrecht, Netherlands
Lattouf, JB:
Univ Montreal Hosp Ctr, Dept Surg Urol, Montreal, PQ, Canada
Lundgren, PO:
Karolinska Univ Hosp, Dept Urol, Stockholm, Sweden
Maher, ER:
Aston Univ, Aston Med Sch, Birmingham, England
Birmingham Womens & Childrens NHS Fdn Trust, Birmingham, England
Cambridge Univ Hosp NHS Fdn Trust, Dept Med Genet, Cambridge, England
Mulders, P:
Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands
Shuch, B:
Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA
Hartmann, A:
Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Fac Med, Bavaria, Germany
Mueller, RU:
Univ Cologne, Dept Internal Med 2, Cologne, Germany
Univ Cologne, Ctr Mol Med, Cologne, Germany
Green Submitted, Green Accepted, hybrid
|